... Methods. Roberto Gnavi 1, Alessandro Migliardi 1, Moreno Demaria 2, Alessio Petrelli 1, Adele Caprioglio 1, Giuseppe Costa 1,3.

Size: px
Start display at page:

Download "... Methods. Roberto Gnavi 1, Alessandro Migliardi 1, Moreno Demaria 2, Alessio Petrelli 1, Adele Caprioglio 1, Giuseppe Costa 1,3."

Transcription

1 European Journal of Public Health, Vol. 17, No. 5, ß The Author Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved. doi: /eurpub/ckm005 Advance Access published on February 15, Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities Roberto Gnavi 1, Alessandro Migliardi 1, Moreno Demaria 2, Alessio Petrelli 1, Adele Caprioglio 1, Giuseppe Costa 1,3 Background: Socio-demographic and clinical characteristics can influence statins prescribing for the secondary prevention of ischaemic heart disease (IHD). We studied the determinants of the prescription of statins in people with IHD in a population in Italy, the country with the lowest prescribing rate in Europe. Methods: All 2001/2002 residents in Torino, aged years, with a hospital discharge diagnosis of IHD were linked to the regional Database of Drug Prescriptions to identify those persons who, within 3 months after discharge, had been prescribed statins. Log-binomial models were used to test statins prescription associations with clinical and socio-demographic characteristics. Results: Statins were prescribed to 31.0% of 7446 patients. Among persons >74 years of age, the prescription rate was 40% lower than that found for younger persons. A positive association was also found for: female gender, being married, a main discharge diagnosis of acute myocardial infarction, revascularization, diabetes and discharge from a cardiology ward. Age was an important effect modifier of the relationship between the prescribing rate and social, but not clinical, determinants. Conclusions: The prevention of IHD with statins is influenced by age, clinical and social factors. The prescribing rate is higher among population groups for whom statins are of proven efficacy. Among patients for whom the efficacy is uncertain, the decision to prescribe is influenced by non-clinical factors, suggesting that there exist both age-based and social-based mechanisims of rationing. Age and social determinants act in concert to further reduce the propensity of physicians to prescribe statins. Keywords: coronary heart disease, drug, Italy, prescriptions, socioeconomic factors, statins... Statins constitute one of the most commonly prescribed drug classes worldwide, and their use continues to increase. 1 The success of these drugs is largely due to their efficacy in reducing blood cholesterol concentration, the low-density lipoprotein fraction, the progression of atheromasic plaque, and, above all, total mortality, cardiac mortality and recourse to revascularization in persons with ischaemic heart disease (IHD). 2 4 Moreover, the spectrum of statins continues to widen, well beyond the initial indications for treating hypercholerestolaemia. 5 7 It is thus reasonable to expect that the indications for the use of statins will be expanded and that the prescribing rate will increase further. In Europe, the prescribing rate for statins greatly varies among individual countries, yet these differences cannot be completely ascribed to differences in morbidity. 1 Italy, the country with the highest public coverage of medicines in Europe, has the lowest prescribing rate, yet this low rate does not seem to correspond to the prevalence of IHD, and in countries such as France, whose IHD prevalence is similar to that of Italy, the prescribing rate is three times higher. It is uncertain if France is overusing or Italy underusing statins and how appropriate is their use in the two countries, but these reports suggest that there exist other factors beyond the frequency of IHD that influence the prescribing rate. Numerous studies have shown that the use of statins in the secondary prevention of IHD is lower than the 1 Epidemiology Unit, ASL 5 Regione Piemonte, Italy 2 Environmental Epidemiolgy Unit, Regional Enviromental Protection Agency of Piedmont, Italy 3 Department of Public Health, University of Turin, Italy Correspondence: Dr Roberto Gnavi, Epidemiology Unit, ASL 5, Via Sabaudia 164, Grugliasco (TO), Italy, tel: þ , fax: þ , roberto.gnavi@epi.piemonte.it recommended levels and that social and demographic characteristics, particularly age, influence the prescribing rate The objective of the present study was to investigate which of a wide range of social and clinical factors influences the start of statins treatment in persons with IHD in the city of Torino, a population with one of the lowest prescribing rates in Europe. Methods Study population The study was conducted in Torino (capital city of the Piemonte Region, northwest Italy, population of ). From the Piemonte Database of Hospitalizations, we extracted records for Torino residents aged 30 to 85 years, who were discharged alive in the period from 1 January 2001 to 31 December 2002 with a diagnosis of IHD (ICD-9-CM codes ) as one of the discharge diagnosis. If the same individual had been hospitalized more than once for IHD, we considered the hospitalization closest to the beginning of the observation period (i.e. closest to 1 January 2001). From the Piemonte Database of Drug Prescriptions, we extracted statin prescriptions (code ATC C10AA) for for persons residing in Torino in the same period. This database contains data on all drug prescriptions made by general practitioners (GP) and public specialists; in Italy, only drugs obtained with a prescription from a GP (or from specialists of the Public Health Service), and not from private physicians, are free of charge. The data from the two registries were linked using an anonymous individual identification key, which allowed us to identify those persons who, after discharge, had been prescribed statins at least once. As use of statin prior to hospital admission is a strong predictor of prescription after hospital discharge, we excluded all patients with a statin

2 Statins for ischaemic heart disease 493 prescription 1-year prior to admission. Patients were defined as statins users if at least one statin was picked from a pharmacy within 3 months after discharge. Patients who died or emigrated from Torino within 3 months from hospital discharge were excluded. The database created by linking the IHD hospitalizations and the statins prescriptions was further linked to the Torino Population Register (TPR), which collects data on all residents of Torino. The TPR data are linked every 10 years to the database of the national census to assign individual socioeconomic variables. was assigned using the data from the 1991 census, or, for people who moved to Torino after this census, using the self-reported information collected by the TPR. 14 These linkage procedures led us to define two groups of persons with IHD: one with at least one prescription of statins (first users) and one without any prescription. For each individual, the following information was available: variables predictive of disease severity, taken from the hospital discharge record (type of diagnosis, associated diseases and performance of revascularization during the observed hospitalization); socio-demographic variables, taken from the TPR (gender, age, educational level and marital status) and a variable that may predict the speciality of the physician most responsible for the care of the patient during the hospital stay, taken from the hospital discharge record (the ward of discharge). Statistical analysis The relation between the prescribing of statins and clinical and socio-demographic variables was investigated by a logbinomial regression model and presented as Prevalence Rate Ratio (PRR), which is a better estimate of the relative risk when the prevalence of the outcome is high. 15 Of the sociodemographic variables taken from the TPR, we used: gender; age class (30 64, 65 74, and years); educational level (elementary school or lower, middle school, high school or college) and marital status (married, unmarried, widowed and divorced/separated). From the Hospital Discharge Database, we used: ward of discharge, aggregated into two classes (either cardiology þ intensive coronary care unit þ heart surgery or other); the performance of revascularization (either PTCA or CABG); the presence of diabetes; and the discharge diagnosis, classified into three classes: main diagnosis of acute myocardial infarction or other acute forms of IHD (AMI) (ICD-9-CM: 410, 411), main diagnosis of chronic IHD ( ), and main diagnosis other than IHD. The models were fitted using PROC GENMODE by SAS System, version 8, and 95% confidence intervals (95% CI) were estimated. Results In the period , of the 7446 Torino residents aged years, who were alive 3 months after discharge from a hospital with a diagnosis of IHD, and with no statins prescription in the 12 months before hospital admission, 2305 (31.0%) had been prescribed statins at least once within 3 months from hospital discharge. The percentage of persons who had received a prescription was highest for the following categories: the youngest age class, men, persons with high educational level, married and divorced persons, persons with a main diagnosis of AMI, persons who had undergone revascularization and persons discharged from a cardiology ward (including intensive coronary care unit and heart surgery). After having adjusted for age, the differences by gender disappeared and the other social differences (education and marital status) decreased, whereas clinical differences were not affected (table 1). Table 2 shows the results of the multivariate model, which includes, in addition to age, all of the other variables listed in table 1. Table 1 Prescribing rate of statins among persons with ischaemic heart disease and prevalence rate ratios (PRR), by social and clinical characteristics; Turin, Italy; Variable Persons with IHD Persons with statin prescription % PRR 95% CI PRR a 95% CI Total Age class (in years) ( ) ( ) Men Women ( ) 0.96 ( ) Elementary or lower Middle school ( ) 1.14 ( ) High school/college ( ) 1.04 ( ) Married Unmarried ( ) 0.64 ( ) Widowed ( ) 0.84 ( ) Separated/divorced ( ) 0.88 ( ) AMI (main diagnosis at discharge) IHD (chronic main diagnosis) ( ) 0.75 ( ) IHD (not main diagnosis) ( ) 0.37 ( ) No Yes ( ) 2.03 ( ) No Yes ( ) 1.02 ( ) Cardiology Other ( ) 0.38 ( ) a: Adjusted for age.

3 494 European Journal of Public Health Among persons greater than 74 years of age, the prescription rate was 40% lower than that found for younger persons, and was slightly lower among men, unmarried and widowed persons; it was slightly higher among persons with intermediate educational level. Regarding the clinical variables, Table 2 Prevalence rate ratios (PRR) for the prescribing of statins among persons with ischaemic heart disease, by social and clinical characteristics; Turin, Italy; Variables PRR 95% CI Age class (in years) ( ) ( ) Men 1 Women 1.09 ( ) Elementary or lower 1 Middle school 1.11 ( ) High school/college 0.99 ( ) Married 1 Unmarried 0.71 ( ) Widowed 0.87 ( ) Separated/divorced 0.89 ( ) AMI (main diagnosis at discharge) 1 IHD (chronic main diagnosis) 0.86 ( ) IHD (not main diagnosis) 0.62 ( ) No 1 Yes 1.39 ( ) No 1 Yes 1.09 ( ) Cardiology 1 other 0.60 ( ) All of the variables have been reciprocally adjusted. the prevalence was highest among persons who had undergone revascularization, persons with diabetes and persons with a main diagnosis at discharge of AMI. Prevalence was highest among persons discharged from a cardiology ward. We thus tested the interaction among age, prescribing rate, and all of the other variables; these were statistically significant for educational level (P < ) and marital status (P ¼ ) and nearly significant for gender (P ¼ ), but for none of the clinical variables. Consequently, the analysis was repeated separately for the three age classes (table 3). In the youngest age class (30 64 years), there were no significant social differences, except for a lower prescribing rate among unmarried and separated/divorced persons, whereas prescribing rate was associated to clinical determinants, as a main diagnosis at discharge of AMI or revascularization, and was highest in persons discharged from cardiology wards. In the intermediate age class (65 74 years), these differences were confirmed, and there was also greater prescribing rate among persons with diabetes and for women (although not statistically significant). Finally, in the oldest age class (75 85 years), there was an association with both clinical determinants and social determinants. Of the clinical determinants, the prescribing rate was highest among persons who had undergone revascularization and lower among persons with a main discharge diagnosis other than IHD. Of the social determinants, the prescribing rate was significantly lower among men, unmarried and widowed persons, and it was higher among persons with the highest educational levels. Among persons discharged from a cardiology ward, the prescription rate was almost double that found for other wards. Discussion The results of this study show that in a large city in Italy, the country with the lowest statins prescribing rate in Europe, fewer than one third of persons discharged from the hospital Table 3 Prevalence rate ratios (PRR) for the prescribing of statins among persons with ischaemic heart disease, by age class; Turin, Italy; Age class (in years) Variable PRR 95% CI PRR 95% CI PRR 95% CI Men Women 0.95 ( ) 1.11 ( ) 1.54 ( ) Elementary or lower Middle school 1.05 ( ) 1.11 ( ) 1.29 ( ) High school/college 0.92 ( ) 1.00 ( ) 1.38 ( ) Married 1 ( ) 1 1 Unmarried 0.68 ( ) 0.80 ( ) 0.52 ( ) Widowed 0.82 ( ) 1.00 ( ) 0.65 ( ) Separated/divorced ( ) 0.75 ( ) AMI (main diagnosis at discharge) IHD (chronic main diagnosis) 0.85 ( ) 0.88 ( ) 0.92 ( ) IHD (not main diagnosis) 0.63 ( ) 0.66 ( ) 0.57 ( ) No Yes 1.36 ( ) 1.38 ( ) 1.49 ( ) No Yes 1.00 ( ) 1.21 ( ) 1.04 ( ) Cardiology Other 0.60 ( ) 0.62 ( ) 0.56 ( ) All of the variables have been reciprocally adjusted.

4 Statins for ischaemic heart disease 495 with a diagnosis of IHD, and without statin prescription within one year before admission, were prescribed statins. As expected, the prescribing rate was correlated with clinical determinants, but also social characteristics of the patients played a role, and this role differed by age. Given that the study was conducted by linking records from different databases, the quality of these databases must be taken into account. The diagnosis of IHD reported on the hospital discharge form is generally considered to be reliable and is commonly used in epidemiological studies. 16 The ATC code for statins reported on GP prescriptions is also considered reliable and used in epidemiological studies. 1 Moreover, the Database on Drug Prescriptions is used to determine reimbursements for drugs, prescription profiles and the medical expenses of GPs for the Piemonte Region: it can thus be reasonably assumed that the existing procedures for controlling this information ensure its accuracy. Another consideration is that this database only contains data on prescriptions made by GPs and not on drugs acquired by patients who obtain a prescription from a private physician, which are not provided free of charge. However, given the high cost of statins, this is probably a rare occurrence and would be more common among the most advantaged social classes; in our study, it would result in an underestimate of the prescribing rate mainly among persons with the highest educational level. An additional limitation in the use of this database is that it is not possible to identify prescriptions that are not picked up at the pharmacy, which is probably more common among persons who have less of a social network on which to rely (e.g. unmarried or widowed persons). In interpreting the results of this study, the quality of the linkage itself must also be considered. The data from the databases were linked using deterministic record linkage, adopting the procedures used in the Torino Longitudinal Study. 14 If the linkage key were of poor quality, errors in linkage could have occurred, such as attributing the prescription to an individual who did not receive it or not attributing the prescription to an individual who did. In either case, the mislinkage would have been caused by errors in recording the variables that constitute the key, and these errors would not be correlated with either the determinants or outcome considered in this study. The prescribing rate of statins for secondary prevention in Torino is lower than the rates reported in other areas of Europe in the same period, but some of these studies included fibrates besides statins, or used slightly different case definitions. 8,17 20 Moreover, in these studies, there was an almost linear inverse association with age 9,10,12,21 whereas in our study age differences were observed only for persons >74 years of age. This is consistent with the results of the large clinical trials, 2,3 which, at the time of our study, did not recommend statins prescription to persons 75 years of age or older. We also found modest gender inequalities, with men being disadvantaged, whereas differences between low and high educational levels were practically nonexistent. The role of gender as a determinant of the prescribing rate is different in different populations, 10,12,22 whereas most studies have shown social differences that disadvantage the less privileged groups. 9,12,13 The higher prescribing rate among married individuals, which has been reported in another study (although the difference was not significant), 12 can be explained by a greater general tendency for this population group to adopt healthy behavioural practices. 23 With regard to the variables directly correlated with disease severity, our results are similar to those reported in other European countries. In particular, the prescribing rate has been reported to be higher among persons with more severe disease, such as those who have undergone revascularization and persons with diabetes. 8,17 Higher prescribing rates have also been reported for patients with a main discharge diagnosis of IHD, compared with those for whom IHD is not the main diagnosis; 12 a secondary diagnosis of IHD is probably indicative of less severe disease (at least as perceived by the treating physician) or of a diagnosis made much earlier, which is negatively correlated both with prescribing 9,12 and with adherence to statins. 24 Another finding of this study is the association between the prescribing rate of statins and the discharge ward, in particular, a strong positive association between the prescribing of statins and having been discharged from the cardiology ward, independently of disease severity, gender, age and educational level. One of the most plausible explanations is that medical specialists tend to treat their patients more aggressively than non-specialists, 25 yet, it is also possible that cardiologists follow the literature on cardiology more attentively, attend scientific speciality meeting where late-breaking results of clinical trial are first presented, and are often the first to be targeted for marketing of new drugs by pharmaceutical companies. 26 Another possible explanation is that, for IHD patients, GPs are more reluctant to make changes in the therapy prescribed by the hospital cardiologist, as opposed to that prescribed by other types of specialists. Another original finding is that the association between the start of statins treatment and the social characteristics of the patients, but not the clinical characteristics, differed by age class. We observed a significant interaction effect between age and social characteristics of patients in the prescription of statins. Age and social determinants acted in concert to further reduce the propensity of physicians to prescribe statins in secondary prevention. The lower use of statins in older age classes could reflect physicians doubts as to the efficacy of statins in persons beyond a certain age and a tendency to be more prudent in treating elderly patients. 27 This phenomenon may be accompanied by a social mechanism; in particular, among the elderly, more disadvantaged persons (low educational level, unmarried or widowed persons) may be even less likely to receive statins. Physicians may be less inclined to prescribe therapies to patients thought unlikely to adhere to treatment. 28 It is not clear why men also fall into this category, yet as stated previously, the role of gender as a determinant is controversial, and men (at least in Italy) may be less likely than women to take care of themselves. In conclusion, although the results of this study cannot be generalized to Italy s entire population they do suggest that the low prescribing rates are associated with factors beyond the low prevalence of IHD. Many patients are not prescribed adequate therapy by either the treating hospital physician or their own GP. Moreover, it is possible that, in light of decreases in the resources available to the National Health System, physicians tend to prescribe statins only to those population groups for whom statins are of proven efficacy. Among patients for whom the efficacy is uncertain, implicit mechanisms of rationing come into play, leading to the exclusion of elderly persons and, among the elderly, those who are socially disadvantaged. To understand to what extent these results can explain the low prescriptions rate of statins in Italy, more studies in different areas of the country are required. From this point of view, this study, limited to the residents of the city of Torino can only be considered as a partial contribution to an intriguing issue of European Public Health. However, it is clear that, in Torino, to improve the prevention of recurrent AMI and death, the transfer of evidence from clinical trials to prescribers must be improved, and areas of uncertainty should be reduced.

5 496 European Journal of Public Health Acknowledgements This study was supported by the 2001 Research Program of the Regione Piemonte Finanaziamento di progetti per iniziative di farmacovigilanza, di informazione degli educatori sanitari, nonchè per le campagne di educazione sanitaria nella stessa materia. Key points Italy is the country with the lowest prescription rate of statins in Europe, but factors influencing prescription rate are poorly known. In , use of statins for secondary prevention of ischaemic heart disease in Torino, Italy, is low and is influenced by age, clinical and social factors. Age and social determinants act in concert to reduce the propensity of physicians to prescribe statins: among the elderly, more disadvantaged persons are less likely to receive statins. There is a need to improve the transfer of evidence from clinical trials to prescribers and to reduce uncertainty. References 1 Walley T, Folino-Gallo P, Schwabe U, et al. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe Br J Clin Pharmacol 2005;60: The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of Cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol level. N Engl J Med 1998;339: Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360: Blauw GJ, Lagaay AM, Smelt AH, et al. Stroke, statins, and cholestrol: a meta-analysis of randomised, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997;28: Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: the prospective pravastatin pooling (PPP) Project. Circulation 2001;103: Euroaspire I and II group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357: DeWilde S, Carey IM, Bremmer SA, et al. Evolution of statin prescribing : a case of agism but not sexism?. Heart 2003;89: Hippisley-Cox J, Pringle M, Crown N, et al. Sex inequalities in ishaemic heart disease in general practice: cross sectional survey. BMJ 2001;322: Whincup P, Emberson J, Lennon L, et al. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart 2002;88: Reid FDA, Cook DG, Whincup PH. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 2002;88: Ward PR, Noyce PR, St Leger AS. Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England. J Epidemiol Community Health 2004;58: Marinacci C, Spadea T, Biggeri A, et al. The role of individual and contextual socioeconomic circumstances on mortality: analysis of time variations in a city of north west Italy. J Epidemiol Community Health 2004;58: Skov T, Deddens J, Petersen MR, et al. Prevalence proportion ratios: estimation and hypotesis testing. Int J Epidemiol 1998;27: Ferrario M, Cesana G, Vanuzzo D, et al. Surveillance of ischaemic heart disease: results from the Italian MONICA populations. Int J Epidemiol 2001;30:S23 S EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Eur Heart J 2001;22: Carroll K, Majeed A, Firth C, et al. Prevalence and management of coronary heart disease in primary care: population-based cross-sectional study using a disease register. J Publ Health Med 2003;25: Hartz I, Eggen AE, Grimsgaard S, et al. Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: the Tromsø study Eur J Clin Pharmacol 2004;60: Rasmussen JN, Gislason GH, Abildstrom SZ, et al. Statin use after acute myocardial infarction: a nationwide study in Denmark. Br J Clin Pharmacol 2005;60: Majeed A, Moser K, Maxwell R. Age, sex and practice variations in the use of statins in general practice in England and Wales. J Pub Health Med 2000;22: Williams D, Bennett K, Feely J. Evidence of an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol 2003;55: Joung IM, Stronks K, van de Mheen H, et al. Health behaviours explain part of the differences in self reported health associated with partner/marital status in The Netherlands. J Epidemiol Community Health 1995;49: Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications. A cross-national study. JAMA 1998;279: Bellotti P, Badano LP, Acquarone N, et al. Specialists-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalised for heart failure: the OSCUR study. Eur Heart J 2001;22: Jackevicius CA, Anderson GM, Leiter L, et al. Use of the statins in patients after acute myocardial infarction. Does evidence change practice? Arch Intern Med 2001;161: Bowling A. Ageism in cardiology. BMJ 1999;319: Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients. The treatment-risk paradox. JAMA 2004;291: Received 18 October 2006, accepted 8 January 2007

Monitoring the prevalence of diabetes and the quality of care using electronic health data

Monitoring the prevalence of diabetes and the quality of care using electronic health data Monitoring the prevalence of diabetes and the quality of care using electronic health data Roberto Gnavi 1 Roberta Picariello 1, Graziella Bruno 2, Carlo Giorda 3, Giuseppe Costa 1,4 1 Epidemiology Unit

More information

T he effectiveness of the hydroxymethyl glutaryl coenzyme

T he effectiveness of the hydroxymethyl glutaryl coenzyme 417 CARDIOVASCULAR MEDICINE Evolution of statin prescribing 1994 1: a case of agism but not of sexism? S DeWilde, I M Carey, S A Bremner, N Richards, S R Hilton, D G Cook... See end of article for authors

More information

JAMA. 2011;305(24): Nora A. Kalagi, MSc

JAMA. 2011;305(24): Nora A. Kalagi, MSc JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for

More information

Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case control analysis

Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case control analysis 752 CARDIOVASCULAR MEDICINE Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case control analysis J Hippisley-Cox, C Coupland... Heart

More information

Aspects of statin prescribing in Norwegian counties with high, average and low statin. Department of Pharmacy, University of Tromsø, Tromsø, Norway

Aspects of statin prescribing in Norwegian counties with high, average and low statin. Department of Pharmacy, University of Tromsø, Tromsø, Norway Title page Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individualised prescription database study Ingeborg Hartz, 1 Solveig Sakshaug, 2 Kari Furu

More information

APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES

APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.

More information

C oronary heart disease (CHD) is a leading cause of morbidity

C oronary heart disease (CHD) is a leading cause of morbidity 229 CARDIOVASCULAR MEDICINE Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study L Wei, J Wang, P Thompson, S Wong, A D Struthers, T M MacDonald...

More information

The All Wales Medicine Strategy Group (AWMSG) is asked to support implementation of the following prescribing indicators.

The All Wales Medicine Strategy Group (AWMSG) is asked to support implementation of the following prescribing indicators. ENCLOSURE 5 APPENDIX 1 Paper presented to AWMSG in June 2006 AWPAG considered comments recorded in AWMSG minutes in July 2006 Paper subsequently updated and brought back to AWMSG for endorsement This paper

More information

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker

More information

Attendance rates and outcomes of cardiac rehabilitation in Victoria, 1998

Attendance rates and outcomes of cardiac rehabilitation in Victoria, 1998 Attendance rates and outcomes of cardiac rehabilitation in Victoria, 1998 CARDIOVASCULAR DISEASE is the leading cause of death in Australia, causing more than 40% of all deaths in 1998. 1 Cardiac rehabilitation

More information

Coronary heart disease prevention and age inequalities:

Coronary heart disease prevention and age inequalities: Coronary heart disease prevention and age inequalities: the first year of the National Service Framework for CHD Julia Hippisley-Cox, Michael Pringle, Ruth Cater, Carol Coupland and Andy Meal ABSTRACT

More information

The important role of cholesterol in the development

The important role of cholesterol in the development Research Recherche The use of cholesterol-lowering medications after coronary revascularization James M. Brophy, Chantal Bourgault, Paul Brassard Abstract Background: In clinical trials, cholesterol-lowering

More information

Audit of cholesterol management among primary care patients in rural southern Italy

Audit of cholesterol management among primary care patients in rural southern Italy O R I G I N A L R E S E A R C H Audit of cholesterol management among primary care patients in rural southern Italy N Buono 1, F Petrazzuoli 1, F D'Addio 1, C Farinaro 1, JK Soler 2 1 National Italian

More information

Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.

Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.

More information

Boehringer Ingelheim Page 6 of 178 Study report for non-interventional studies based on existing data BI Study Number

Boehringer Ingelheim Page 6 of 178 Study report for non-interventional studies based on existing data BI Study Number Page 6 of 178 report for non-interventional studies based on existing data BI Number 1160.144 c14462719-01 International GmbH or one or more of its affiliated companies 1. ABSTRACT Title of study: Keywords:

More information

rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.

rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

Cite this article as: BMJ, doi: /bmj f (published 24 March 2005)

Cite this article as: BMJ, doi: /bmj f (published 24 March 2005) Cite this article as: BMJ, doi:10.1136/bmj.38398.408032.8f (published 24 March 2005) Primary care Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison

More information

Rates and patterns of participation in cardiac rehabilitation in Victoria

Rates and patterns of participation in cardiac rehabilitation in Victoria Rates and patterns of participation in cardiac rehabilitation in Victoria Vijaya Sundararajan, MD, MPH, Stephen Begg, MS, Michael Ackland, MBBS, MPH, FAPHM, Ric Marshall, PhD Victorian Department of Human

More information

Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines

Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease

More information

Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke

Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke «L Europe de la santé au service des patients» 13-14 October 2008 - Institut Pasteur Paris Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke Simona Giampaoli National Centre of

More information

The Framingham Coronary Heart Disease Risk Score

The Framingham Coronary Heart Disease Risk Score Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although

More information

CLINICAL. Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population

CLINICAL. Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population Jennifer S. Schultz, PhD; John C. O Donnell, PhD; Ken L. McDonough, MD;

More information

Finland and Sweden and UK GP-HOSP datasets

Finland and Sweden and UK GP-HOSP datasets Web appendix: Supplementary material Table 1 Specific diagnosis codes used to identify bladder cancer cases in each dataset Finland and Sweden and UK GP-HOSP datasets Netherlands hospital and cancer registry

More information

Updated cost utility analysis for statins

Updated cost utility analysis for statins Updated cost utility analysis for statins Scott Metcalfe Pharmac 30 January 2001 Pharmac estimates the cost-utility of providing statins to everyone with dyslipidaemia and > 10% 5-year absolute risk of

More information

Statins in the elderly: What evidence of their benefit in prevention?

Statins in the elderly: What evidence of their benefit in prevention? Archives of Cardiovascular Disease (2010) 103, 61 65 SCIENTIFIC EDITORIAL Statins in the elderly: What evidence of their benefit in prevention? Les statines chez les personnes âgées : quelle preuve de

More information

Comments from AstraZeneca UK Ltd

Comments from AstraZeneca UK Ltd 13 June 2007 NICE HTA: Ezetimibe for the treatment of primary (heterozygous familial and nonfamilial) hypercholesterolemia Appraisal Consultation Document (ACD) Many thanks for providing the ACD for the

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:

More information

The Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP

The Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP The Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP Professor of Medicine, Endowed Chair in Patient Health Management, Health Scholar of the Alberta Heritage Foundation,

More information

Statins and newly diagnosed diabetes

Statins and newly diagnosed diabetes DOI:10.1111/j.1365-2125.2004.02142.x British Journal of Clinical Pharmacology Statins and newly diagnosed diabetes Susan S. Jick & Brian D. Bradbury Boston Collaborative Drug Surveillance Program, 11 Muzzey

More information

Management of ischaemic heart disease in primary care: towards better practice

Management of ischaemic heart disease in primary care: towards better practice Journal of Public Health Medicine Vol. 21, No. 2, pp. 179 184 Printed in Great Britain Management of ischaemic heart disease in primary care: towards better practice Krish Thiru, Jeremy Gray and Azeem

More information

Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review

Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review British Journal of Clinical Pharmacology DOI:10.1111/bcp.12339 Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review Mary A. De Vera, 1,2 Vidula Bhole, 2 Lindsay

More information

The problem of uncontrolled hypertension

The problem of uncontrolled hypertension (2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands

More information

A bs tr ac t. n engl j med 357;15 october 11,

A bs tr ac t. n engl j med 357;15   october 11, The new england journal of medicine established in 1812 october 11, 2007 vol. 357 no. 15 Long-Term Follow-up of the West of Scotland Coronary Prevention Study Ian Ford, Ph.D., Heather Murray, M.Sc., Chris

More information

Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals

Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia

More information

Quality ID #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Quality ID #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care Quality ID #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

DETERMINANTS OF QUALITY IN DIABETES CARE PROCESS: THE POPULATION BASED TORINO STUDY

DETERMINANTS OF QUALITY IN DIABETES CARE PROCESS: THE POPULATION BASED TORINO STUDY Diabetes Care Publish Ahead of Print, published online August 12, 2009 DETERMINANTS OF QUALITY IN DIABETES CARE PROCESS: THE POPULATION BASED TORINO STUDY Roberto Gnavi MD 1, Roberta Picariello BSc 1,

More information

THE PAST DECADE HAS WITnessed

THE PAST DECADE HAS WITnessed SPECIAL COMMUNICATION Clinical Goals and Performance Measures for Cholesterol Management in Secondary Prevention of Coronary Heart Disease Thomas H. Lee, MD James I. Cleeman, MD Scott M. Grundy, MD Clayton

More information

Medical evidence suggests that

Medical evidence suggests that COMBINATION THERAPY TO ACHIEVE LIPID GOALS David G. Robertson, MD* ABSTRACT Coronary heart disease (CHD) remains the leading cause of death in the United States despite recent advances in treatment and

More information

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict

More information

Statins in the elderly : Is there a rationale?

Statins in the elderly : Is there a rationale? Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29

More information

Treatment disparities for patients diagnosed with metastatic bladder cancer in California

Treatment disparities for patients diagnosed with metastatic bladder cancer in California Treatment disparities for patients diagnosed with metastatic bladder cancer in California Rosemary D. Cress, Dr. PH, Amy Klapheke, MPH Public Health Institute Cancer Registry of Greater California Introduction

More information

Preventive Cardiology Scientific evidence

Preventive Cardiology Scientific evidence Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention

More information

Missed opportunities for secondary prevention of cerebrovascular disease in elderly British men from 1999 to 2005: a population-based study

Missed opportunities for secondary prevention of cerebrovascular disease in elderly British men from 1999 to 2005: a population-based study Journal of Public Health Vol. 29, No. 3, pp. 251 257 doi:10.1093/pubmed/fdm040 Advance Access Publication 21 June 2007 Missed opportunities for secondary prevention of cerebrovascular disease in elderly

More information

Is Lower Better for LDL or is there a Sweet Spot

Is Lower Better for LDL or is there a Sweet Spot Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,

More information

D espite a distinct decline in ischaemic heart disease

D espite a distinct decline in ischaemic heart disease RESEARCH REPORT Can cardiovascular risk factors and lifestyle explain the educational inequalities in mortality from ischaemic heart disease and from other heart diseases? 26 year follow up of 50 000 Norwegian

More information

Data Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.

Data Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease. 1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association

More information

Repeat ischaemic heart disease audit of primary care patients ( ): Comparisons by age, sex and ethnic group

Repeat ischaemic heart disease audit of primary care patients ( ): Comparisons by age, sex and ethnic group Repeat ischaemic heart disease audit of primary care patients (2002-2003): Comparisons by age, sex and ethnic group Baseline-repeat ischaemic heart disease audit of primary care patients: a comparison

More information

Inter-regional differences and outcome in unstable angina

Inter-regional differences and outcome in unstable angina European Heart Journal (2000) 21, 1433 1439 doi:10.1053/euhj.1999.1983, available online at http://www.idealibrary.com on Inter-regional differences and outcome in unstable angina Analysis of the International

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Olesen JB, Lip GYH, Kamper A-L, et al. Stroke and bleeding

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Gutierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med. 2012;172(12):IRA120005.

More information

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients

More information

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies

More information

NIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2014 June 24.

NIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2014 June 24. NIH Public Access Author Manuscript Published in final edited form as: JAMA Intern Med. 2013 June 24; 173(12): 1150 1151. doi:10.1001/jamainternmed.2013.910. SSRI Use, Depression and Long-Term Outcomes

More information

Cardiovascular and Cancer Mortality in Very Elderly Post-Myocardial Infarction Patients Receiving Statin Treatment

Cardiovascular and Cancer Mortality in Very Elderly Post-Myocardial Infarction Patients Receiving Statin Treatment Journal of the American College of Cardiology Vol. 55, No. 13, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.01.013

More information

Cardiac Rehabilitation after Primary Coronary Intervention CONTRA

Cardiac Rehabilitation after Primary Coronary Intervention CONTRA DEBATE SESSION Is there a role for cardiac rehabilitation in the modern era of Percutaneous coronary intervention and coronary artery bypass grafting? Cardiac Rehabilitation after Primary Coronary Intervention

More information

This is the publisher s copyrighted version of this article.

This is the publisher s copyrighted version of this article. Archived at the Flinders Academic Commons http://dspace.flinders.edu.au/dspace/ This is the publisher s copyrighted version of this article. The original can be found at: http://www.dovepress.com/differential-associations-betweenactual-and-expected-gp-practice-pres-peer-reviewed-article-tcrm

More information

Threshold Level or Not for Low-Density Lipoprotein Cholesterol

Threshold Level or Not for Low-Density Lipoprotein Cholesterol ... SYMPOSIA PROCEEDINGS... Threshold Level or Not for Low-Density Lipoprotein Cholesterol Based on a debate between Philip J. Barter, MD, PhD, FRACP, and Frank M. Sacks, MD Debate Summary As drugs, such

More information

Cost of lipid lowering in patients with coronary artery disease by Case Method Learning Kiessling A, Zethraeus N, Henriksson P

Cost of lipid lowering in patients with coronary artery disease by Case Method Learning Kiessling A, Zethraeus N, Henriksson P Cost of lipid lowering in patients with coronary artery disease by Case Method Learning Kiessling A, Zethraeus N, Henriksson P Record Status This is a critical abstract of an economic evaluation that meets

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

STATINS (3-HYDROXY-3-METHYLglutaryl

STATINS (3-HYDROXY-3-METHYLglutaryl ORIGINAL CONTRIBUTION Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes Cynthia A. Jackevicius, BScPhm, MSc, FCSHP Muhammad Mamdani, PharmD, MA, MPH Jack V. Tu,

More information

Cost effectiveness of statin therapy for the primary prevention of coronary heart disease in Ireland Nash A, Barry M, Walshe V

Cost effectiveness of statin therapy for the primary prevention of coronary heart disease in Ireland Nash A, Barry M, Walshe V Cost effectiveness of statin therapy for the primary prevention of coronary heart disease in Ireland Nash A, Barry M, Walshe V Record Status This is a critical abstract of an economic evaluation that meets

More information

Belinda Green, Cardiologist, SDHB, 2016

Belinda Green, Cardiologist, SDHB, 2016 Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens

More information

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. 2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality

More information

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,

More information

Statins after 80 years old. Pros/Cons symposium. 13 th EUGMS Congress Nice Sept 2017

Statins after 80 years old. Pros/Cons symposium. 13 th EUGMS Congress Nice Sept 2017 Statins after 80 years old Pros/Cons symposium 13 th EUGMS Congress Nice 20-22 Sept 2017 Athanasios Benetos Conflict of interest: None The Statinissean War Two fearless fighters Athanasios the Athenian

More information

LIST OF ABBREVIATIONS

LIST OF ABBREVIATIONS Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,

More information

REPORT FROM THE CANADIAN CHRONIC DISEASE SURVEILLANCE SYSTEM:

REPORT FROM THE CANADIAN CHRONIC DISEASE SURVEILLANCE SYSTEM: REPORT FROM THE CANADIAN CHRONIC DISEASE SURVEILLANCE SYSTEM: PROTECTING AND EMPOWERING CANADIANS TO IMPROVE THEIR HEALTH TO PROMOTE AND PROTECT THE HEALTH OF CANADIANS THROUGH LEADERSHIP, PARTNERSHIP,

More information

Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database

Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database open access Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database Yana Vinogradova, 1 Carol Coupland, 1 Peter Brindle, 2,3 Julia Hippisley-Cox

More information

National Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008

National Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008 Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It

More information

Lipid Panel Management Refresher Course for the Family Physician

Lipid Panel Management Refresher Course for the Family Physician Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new

More information

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,

More information

Aspirin and Statin Use in the NMMC Adult Cardiology Clinic

Aspirin and Statin Use in the NMMC Adult Cardiology Clinic American University of Armenia Center for Health Services Research and Development Nork Marash Medical Center Aspirin and Statin Use in the NMMC Adult Cardiology Clinic Zaruhi Bakalyan, MD, MPH Anahit

More information

Is it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany

Is it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany Is it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany Is it worth offering cardiovascular disease prevention to the elderly?

More information

Relationship between body mass index and length of hospital stay for gallbladder disease

Relationship between body mass index and length of hospital stay for gallbladder disease Journal of Public Health Vol. 30, No. 2, pp. 161 166 doi:10.1093/pubmed/fdn011 Advance Access Publication 27 February 2008 Relationship between body mass index and length of hospital stay for gallbladder

More information

Zhao Y Y et al. Ann Intern Med 2012;156:

Zhao Y Y et al. Ann Intern Med 2012;156: Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled

More information

D ecreasing total and low density lipoprotein cholesterol

D ecreasing total and low density lipoprotein cholesterol 25 CARDIOVASCULAR MEDICINE Low prevalence of lipid lowering drug use in older men with established coronary heart disease P H Whincup, J R Emberson, L Lennon, M Walker, O Papacosta, A Thomson... See end

More information

GUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES

GUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES GUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES Prepared by DCPNS Action Committee Dr. Lynne Harrigan Brenda Cook Peggy Dunbar Bev Harpell with the assistance

More information

TAVI SURVEY. Performed by the ESC Council for Cardiology Practice

TAVI SURVEY. Performed by the ESC Council for Cardiology Practice TAVI SURVEY Performed by the ESC Council for Cardiology Practice BACKGROUND To evaluate the knowledge and the behaviour of a large community of cardiologists working in different settings, both in hospital

More information

Using routinely collected clinical data to support Clinical Trials: a view from Scotland

Using routinely collected clinical data to support Clinical Trials: a view from Scotland Using routinely collected clinical data to support Clinical Trials: a view from Scotland Professor Colin McCowan Robertson Centre for Biostatistics and Glasgow Clinical Trials Unit From birth to death

More information

Cardiovascular disease (CVD) is the

Cardiovascular disease (CVD) is the Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Cost Effectiveness of Statin Therapy for the Primary Prevention of Major Coronary Events in Individuals With Type 2 Diabetes

More information

NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT

NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT CONTENTS PATIENTS ADMITTED WITH HEART FAILURE...4 Demographics... 4 Trends in Symptoms... 4 Causes and Comorbidities

More information

Proof of Concept: NHS Wales Atlas of Variation for Cardiovascular Disease. Produced on behalf of NHS Wales and Welsh Government

Proof of Concept: NHS Wales Atlas of Variation for Cardiovascular Disease. Produced on behalf of NHS Wales and Welsh Government Proof of Concept: NHS Wales Atlas of Variation for Cardiovascular Disease Produced on behalf of NHS Wales and Welsh Government April 2018 Table of Contents Introduction... 3 Variation in health services...

More information

Chapter V Depression and Women with Spinal Cord Injury

Chapter V Depression and Women with Spinal Cord Injury 1 Chapter V Depression and Women with Spinal Cord Injury L ike all women with disabilities, women with spinal cord injury (SCI) may be at an elevated risk for depression due to the double jeopardy of being

More information

NON STEROIDEAL ANTI-INFLAMMATORY DRUGS AND CARDIOVASCULAR RISK. Advances in Cardiac Arrhythmias and Great Innovations in Cardiology

NON STEROIDEAL ANTI-INFLAMMATORY DRUGS AND CARDIOVASCULAR RISK. Advances in Cardiac Arrhythmias and Great Innovations in Cardiology NON STEROIDEAL ANTI-INFLAMMATORY DRUGS AND CARDIOVASCULAR RISK Advances in Cardiac Arrhythmias and Great Innovations in Cardiology Torino, October 15, 2016 Giuseppe Di Pasquale Direttore Dipartimento Medico

More information

the high CVD risk smoker

the high CVD risk smoker Smoking Cessation: population and patients A comprehensive approach to the smoker the high CVD risk smoker Catriona Jennings Cardiovascular Specialist Research Nurse Imperial College London European Society

More information

8/10/2012. Education level and diabetes risk: The EPIC-InterAct study AIM. Background. Case-cohort design. Int J Epidemiol 2012 (in press)

8/10/2012. Education level and diabetes risk: The EPIC-InterAct study AIM. Background. Case-cohort design. Int J Epidemiol 2012 (in press) Education level and diabetes risk: The EPIC-InterAct study 50 authors from European countries Int J Epidemiol 2012 (in press) Background Type 2 diabetes mellitus (T2DM) is one of the most common chronic

More information

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

More information

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic

More information

Chronic conditions, physical function and health care use:

Chronic conditions, physical function and health care use: Chronic conditions, physical function and health care use: Findings from the Australian Longitudinal Study on Women s Health Authors: Julie Byles Richard Hockey Deirdre McLaughlin Annette Dobson Wendy

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories

More information

The University of Mississippi School of Pharmacy

The University of Mississippi School of Pharmacy LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.

More information

Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany

Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany The demographic issue Life expectancy is increasing Patients are getting

More information

Lipid Management Step Therapy Criteria with Medical Diagnoses Option*

Lipid Management Step Therapy Criteria with Medical Diagnoses Option* Lipid Management Step Therapy Criteria with Medical Diagnoses Option* * Medical diagnoses are required for implementation of this option. Program may be implemented with the following options: Option One

More information

had non-continuous enrolment in Medicare Part A or Part B during the year following initial admission;

had non-continuous enrolment in Medicare Part A or Part B during the year following initial admission; Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among Medicare beneficiaries Weiss J P, Saynina O, McDonald K M, McClellan M

More information

Populations Interventions Comparators Outcomes Individuals: With diagnosed heart disease. rehabilitation

Populations Interventions Comparators Outcomes Individuals: With diagnosed heart disease. rehabilitation Protocol Cardiac Rehabilitation in the Outpatient Setting (80308) Medical Benefit Effective Date: 01/01/17 Next Review Date: 05/18 Preauthorization No Review Dates: 07/07, 07/08, 05/09, 05/10, 05/11, 05/12,

More information